Showing results (11-20 of 134) with videos related to
Sort By:
Pageof 14
European Urology|April 3, 2021
New Insights into Adjuvant Therapy in Renal Cell Carcinoma: Is the Chapter of VEGF Inhibitors Definitely Closed?Florent Peyraud, Mathieu Larroquette, Alain Ravaud, et al.Cancer|April 30, 2009
Sequential therapy in renal cell carcinomaBernard Escudier, Marine Gross Goupil, Christophe Massard, et al.Immunotherapy|April 28, 2021
Colitis presenting 5 months after the final dose of anti-PD-1: long-term monitoring is warranted after adjuvant therapyCharlotte Domblides, Marine Gross-Goupil, Alain Ravaud, et al.Targeted Oncology|January 4, 2013
Prolonged efficacy of mTOR inhibitors in papillary renal cell carcinoma: progression-free survival lasting for over 3 years, a case report and review of the literatureAmaury Daste, Marine Gross-Goupil, Sophie Roca, et al.Expert Opinion on Biological Therapy|July 10, 2019
Which place for avelumab in the management of urothelial carcinoma?Mathieu Larroquette, Marine Gross-Goupil, Amaury Daste, et al.Investigational New Drugs|June 24, 2009
Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinomaJudith Michels, Nathalie Lassau, Marine Gross-Goupil, et al.Onkologie|March 11, 2010
Can a cure be achieved with taxane-based chemotherapy plus surgery in patients with primary mediastinal non-seminomatous germ cell tumors and progression or relapse despite first-line chemotherapy?Vera Miskovska, Antonin Levy, Christophe C Massard, et al.Journal of Surgical Case Reports|December 15, 2022
Feasibility of robotic-assisted partial nephrectomy for complete remission of metastatic renal cell carcinoma after long exposure to immune checkpoint inhibitors (UroCCR-106)Samy Mebroukine, Mokrane Yacoub, Clément Michiels, et al.Therapeutics and Clinical Risk Management|June 9, 2022
An Evaluation of Cabozantinib for the Treatment of Renal Cell Carcinoma: Focus on Patient Selection and PerspectivesRomain Iaxx, Felix Lefort, Charlotte Domblides, et al.Pageof 14